Investigational drug · Phase 3
BL-M14D1
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "BL-M14D1"
First trial start
2026
Jul 9, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BL-M14D1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer Extensive Stage
- Small-cell Lung Cancer
- Small Cell Carcinoma
- Sclc
- SCLC,Extensive Stage
- Lung Cancer
- Lung Cancer Metastatic
- Lung Cancer Stage IV
- Extensive-stage Small-cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BL-M14D1" as an intervention, largest first.
- BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)Pivotal-lookingRecruiting
SystImmune Inc.Industry
NCT07625644 · 550 participants (planned) · Start Aug 4, 2026 · Primary completion Jan 2030
Drug: BL-M14D1 and Atezolizumab; Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin · For: Small Cell Lung Cancer Extensive Stage; Small-cell Lung Cancer; Small Cell Carcinoma and 5 more
Sites: Springdale, Arkansas; Glendale, California; Long Beach, California · 84 sites in all
SystImmune Inc.Industry
NCT07080242 · 120 participants (planned) · Start Apr 28, 2025 · Primary completion Dec 31, 2027
Drug: BL-M14D1 · For: Small Cell Lung Cancer Metastatic or Locally Advanced; Neuroendocrine Cancer; Metastatic Neuroendocrine Prostate Cancer and 8 more
Sites: Huntsville, Alabama; Glendale, California; Long Beach, California · 32 sites in all
Biokin (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT06505824 · 115 participants (planned) · Start Aug 2, 2024 · Primary completion Jun 2027
Drug: BL-M14D1 · For: Small Cell Lung Cancer; Neuroendocrine Tumors
Sites: Shanghai, China
Biokin (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07654400 · 36 participants (planned) · Start Jul 9, 2026 · Primary completion Dec 2027
Drug: BL-M14D1; Atezolizumab · For: Extensive-stage Small-cell Lung Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers.
· Cancer Discov 2026
Also in development for Small Cell Lung Cancer Extensive Stage
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- GocatamigHPN328, MK-6070Phase 34 trials
Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer
- Atezolizumab followed by AtezolizumabPhase 31 trial
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- quaratusugene ozeplasmidREQORSAPhase 22 trials
Genprex, Inc. · Carcinoma, Non-Small Cell Lung, Small Cell Lung Cancer Extensive Stage
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.